Pierre Riviere
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$10.4MFederal grants as PI17 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
17 awards · $10.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 18, 2022 | NIH | SBIR Phase I Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment | $199K | PEPTIDE LOGIC LLC |
| Aug 5, 2022 | NIH | SBIR Phase I Peptide-antibody conjugate kappa-opioid receptor (PAC-KOR) agonists for treatment of chronic itch | $499K | PEPTIDE LOGIC LLC |
| Jun 14, 2022 | NIH | SBIR Phase I Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes | $199K | PEPTIDE LOGIC LLC |
| Sep 8, 2021 | NIH | SBIR Phase I Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment | $499K | PEPTIDE LOGIC LLC |
| Jul 1, 2021 | NIH | SBIR Phase I Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes | $696K | PEPTIDE LOGIC LLC |
| Jun 25, 2021 | NIH | SBIR Phase I Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes | $497K | PEPTIDE LOGIC LLC |
| Aug 4, 2020 | NIH | SBIR Phase II Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain | $1.4M | PEPTIDE LOGIC LLC |
| Sep 23, 2019 | NIH | SBIR Phase II Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain | $1.6M | PEPTIDE LOGIC LLC |
| Jul 12, 2019 | NIH | SBIR Phase II Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain | $1.4M | PEPTIDE LOGIC LLC |
| Mar 4, 2019 | NIH | SBIR Phase I Peripherally-restricted and long-acting MAS1(LA-MAS1) agonists for pain | $348K | PEPTIDE LOGIC LLC |
| Sep 10, 2018 | NIH | SBIR Phase I PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN | $261K | PEPTIDE LOGIC LLC |
| Jul 31, 2018 | NIH | SBIR Phase II Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain | $1.5M | PEPTIDE LOGIC LLC |
| Dec 13, 2017 | NIH | SBIR Phase I PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN | $279K | PEPTIDE LOGIC LLC |
| Sep 1, 2017 | NIH | SBIR Phase I Bi Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis | $298K | PEPTIDE LOGIC LLC |
| Aug 24, 2017 | NIH | SBIR Phase I Bi-Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis | $298K | PEPTIDE LOGIC LLC |
| Aug 1, 2016 | NIH | SBIR Phase I Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain | $207K | PEPTIDE LOGIC LLC |
| Jul 5, 2016 | NIH | SBIR Phase I Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain | $207K | PEPTIDE LOGIC LLC |
Peer ranks
Federal funding#57
Awards as PI#29
Patents#273
Companies
- PEPTIDE LOGIC LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.